Drug profile · INN
adapalene
EPIDUO
adapalene (EPIDUO) is a retinoic acid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — adapalene
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 3
- Programs
- 3
- Data quality
- 0.84
Quick answer
adapalene (EPIDUO) is a retinoic acid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Retinoic acid receptor agonist
Primary target: Retinoic acid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11273132
Topical dapsone and dapsone/adapalene compositions and methods for use thereof
granted -
US 8871447
Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
granted -
US 6723695
CTL epitopes from EBV
expired
Frequently asked questions
What is adapalene?
adapalene (EPIDUO) is a retinoic acid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for adapalene?
EPIDUO is a marketed brand name for adapalene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of adapalene?
adapalene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.